Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$29.15 USD

29.15
263,087

-0.08 (-0.27%)

Updated Nov 13, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Top Ranked Momentum Stocks to Buy for November 13th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 13th

Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

by Zacks Equity Research

Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis

by Zacks Equity Research

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus

by Zacks Equity Research

Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.

Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

by Zacks Equity Research

Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.

Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales

by Zacks Equity Research

Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.

Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.

Zacks.com featured highlights include: Qualys, Fortinet, Zumiez, Commvault Systems and Alkermes

by Zacks Equity Research

Zacks.com featured highlights include: Qualys, Fortinet, Zumiez, Commvault Systems and Alkermes

Check 5 Best Liquid Stocks for Impressive Returns

by Zacks Equity Research

Here are five top-ranked liquid stocks that investors can bank on for remarkable returns.

Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View

by Zacks Equity Research

Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.

All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy

by Zacks Equity Research

Alkermes (ALKS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3

by Zacks Equity Research

Alkermes (ALKS) beats estimates in the third quarter of 2019. Its proprietary products, especially Aristada, drive revenues.

Alkermes (ALKS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 80.00% and 1.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More

by Zacks Equity Research

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.

Biogen Strengthens MS & SMA Portfolio as Competition Lurks

by Zacks Equity Research

Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.

Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy

by Zacks Equity Research

Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex

Why Is Alkermes (ALKS) Down 3.9% Since Last Earnings Report?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

by Zacks Equity Research

Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

by Zacks Equity Research

Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.

Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2

by Zacks Equity Research

Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.

Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 190.00% and 10.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Alkermes (ALKS) Q2 Earnings Expected to Decline

by Zacks Equity Research

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

by Zacks Equity Research

Key highlights of the past week include collaborations and other pipeline updates.